1. GlaxoSmithKline. GSK announces FDA advisory committee votes in favour of positive benefit/risk profile for belantamab mafodotin for patients with relapsed/refractory multiple myeloma [media release]. 14 Jul 2020. https://www.gsk.com.
2. GlaxoSmithKline. BLENREP (belantamab mafodotin-blmf): US prescribing information. 2020. https://www.accessdata.fda.gov/. Accessed 7 Aug 2020.
3. BioWa Inc. BioWa announces licensing of BioWa′s POTELLIGENT(R) technology by GlaxoSmithkline for use in antibody research and development. [media release]. 19 Oct 2007. http://www.biowa.com.
4. Seattle Genetics. Seattle Genetics announces antibody-drug conjugate collaboration with GlaxoSmithKline [media release]. 22 Dec 2009. http://www.seattlegenetics.com.
5. GlaxoSmithKline. Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/ refractory multiple myeloma [media release]. 16 Dec 2019. https://www.gsk.com.